4-methoxy-N,2-dimethylaniline | 86735-53-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 4-methoxy-N,2-dimethylaniline
• CAS: 86735-53-7
• 化学式: C₉H₁₃NO
• 分子量: 151.208
• InChiKey: MZMCAKDBWLUQPE-UHFFFAOYSA-N

物化性质

• 沸点：
  256.9±28.0 °C(Predicted)
• 密度：
  1.013±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  21.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-methoxy-N,2-dimethylaniline 在 吡啶 、 盐酸 、 正丁基锂 、 tetraphosphorus decasulfide 、 air 、 氢溴酸 、 sodium hydride 、 sodium carbonate 、 溶剂黄146 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 25.0h， 生成 2,2'-dithiobis [N-phenyl-5-acetoxy-1-methylindolyl-3-carboxamide]
  参考文献：
  名称：

  Tyrosine Kinase Inhibitors. 3. Structure-Activity Relationships for Inhibition of Protein Tyrosine Kinases by Nuclear-Substituted Derivatives of 2,2'-Dithiobis(1-methyl-N-phenyl-1H-indole-3-carboxamide)

  摘要：

  A series of indole-substituted 2,2'-dithiobis(1-methyl-N-phenyl-1H-indole-3-carboxamides) were prepared and evaluated for their ability to inhibit the tyrosine kinase activity of both the epidermal growth factor receptor (EGFR) and the nonreceptor pp60(v-src) tyrosine kinase. The compounds were synthesized by conversion of appropriate 1-methyloxindoles to 1-methyl-2-indolinethiones with P2S5 followed by subsequent reaction with NaH and phenyl isocyanate and oxidative dimerization of the resulting 2,3-dihydro-N-phenyl-2-thioxo-1H-indole-3-carboxamides. The parent compound and many of the substituted analogues were moderately potent inhibitors of both kinase enzymes, but no clear relationships were seen between substitution on the indole ring and inhibitory activity, While 4-substituted compounds were generally inactive, 5-substituted derivatives with electron-withdrawing groups showed inhibitory activity. However, none of the substituted compounds showed significantly better activity than the unsubstituted parent compound. There was generally a good correlation between activity against the EGFR and pp60(v-src) kinases, but several compounds did show some specificity (>20-fold) of inhibition; 5-Cl and 5-Br derivatives preferentially inhibited pp60(v-src), while the 5-CF3 compound preferentially inhibited EGFR. Selected compounds from the series were found to inhibit the growth of Swiss 3T3 fibroblasts with IC(50)s in the range 2-25 mu M, the most active being 4-substituted derivatives. The compounds inhibited bFGF-mediated protein tyrosine phosphorylation in intact cells more effectively than EGFR- or PDGF-mediated phosphorylation.

  DOI：

  10.1021/jm00039a016
• 作为产物：
  描述：

  2-甲基-4-甲氧基苯胺 在 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 24.0h， 生成 4-methoxy-N,2-dimethylaniline
  参考文献：
  名称：

  新型N（9）甲基化AHMA类似物的合成与抗肿瘤活性†

  摘要：

  描述了一种新型抗肿瘤N（9）-甲基-3-（9-amino啶基氨基）-5-羟甲基苯胺（AHMA）衍生物的合成方法。氨基苯甲酸的Boc保护，然后LiAlH 4还原，得到了新颖的甲基氨基苄醇反应物。他们与9-氯ac啶提供N（9）-甲基化的AHMA衍生物用于生物筛选。针对七种癌细胞系的初步抗增殖试验确定了具有低μMIC 50值的化合物。

  DOI：

  10.1039/c2nj40567a

文献信息

• A Metal‐Free Direct Arene C−H Amination
  作者：Tao Wang、Marvin Hoffmann、Andreas Dreuw、Edina Hasagić、Chao Hu、Philipp M. Stein、Sina Witzel、Hongwei Shi、Yangyang Yang、Matthias Rudolph、Fabian Stuck、Frank Rominger、Marion Kerscher、Peter Comba、A. Stephen K. Hashmi

  DOI：10.1002/adsc.202100236

  日期：2021.6.8

  The synthesis of aryl amines via the formation of a C−N bond is an essential tool for the preparation of functional materials, active pharmaceutical ingredients and bioactive products. Usually, this chemical connection is only possible by transition metal-catalyzed reactions, photochemistry or electrochemistry. Here, we report a metal-free arene C−H amination using hydroxylamine derivatives under benign

  通过形成 CN 键合成芳胺是制备功能材料、活性药物成分和生物活性产品的重要工具。通常，这种化学连接只能通过过渡金属催化的反应、光化学或电化学来实现。在这里，我们报告了在良性条件下使用羟胺衍生物进行的无金属芳烃 C-H 胺化。即使在存在各种官能团的情况下，胺化试剂 TsONHR 和芳烃底物之间的电荷转移相互作用也能实现芳烃的化学选择性胺化。氧气对于有效转化至关重要，其对电子转移步骤的加速作用已通过实验证明。此外，
• [EN] 2- [ (2-{PHENYLAMINO}-1H-PYRROLO [2, 3-D] PYRIMIDIN-4-YL) AMINO] BENZAMIDE DERIVATIVES AS IGF-1R INHIBITORS FOR THE TREATMENT OF CANCER<br/>[FR] DÉRIVÉS DE 2-[(2-{PHÉNYLAMINO}-1H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)AMINO]BENZAMIDE EN TANT QU'INHIBITEUR D'IGF-1R POUR LE TRAITEMENT DU CANCER
  申请人：SMITHKLINE BEECHAM CORP

  公开号：WO2009020990A1

  公开（公告）日：2009-02-12

  Novel pyrrolopyrimidines as shown in formula (I) and pharmaceutically acceptable derivatives thereof. The compounds are useful in the inhibition of IGF-1R.

  新型吡咯吡嘧啶如公式(I)所示，及其药用可接受的衍生物。这些化合物在抑制IGF-1R方面是有用的。
• [EN] INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION<br/>[FR] INHIBITEURS DE LA RÉPLICATION DU VIRUS D'IMMUNODÉFICIENCE HUMAINE
  申请人：VIIV HEALTHCARE (NO 5) LTD

  公开号：WO2016172425A1

  公开（公告）日：2016-10-27

  Compounds of Formulas I-VI, including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth. Formula I is exemplified below: Formula (i)

  公式I-VI的化合物，包括其药用可接受的盐，以及用于治疗人类免疫缺陷病毒（HIV）感染的组合物和方法。公式I如下所示：公式（i）
• Visible light-induced recyclable g-C₃N₄ catalyzed thiocyanation of C(sp²)–H bonds in sustainable solvents
  作者：Fan-Lin Zeng、Hu-Lin Zhu、Xiao-Lan Chen、Ling-Bo Qu、Bing Yu

  DOI：10.1039/d1gc00938a

  日期：——

  inexpensive NH4SCN has been developed using carbon nitride (g-C3N4) as a general heterogeneous catalyst in a green solvent under an air atmosphere and the irradiation of a blue LED. Various thiocyanated heterocycles including indolo[2,1-a]isoquinolin-6(5H)-ones, benzimidazo[2,1-a]isoquinolin-6(5H)-ones, thioflavones, azaspiro[4.5]trienones and imidazo[1,2-a]pyridines were successfully synthesized in good

  已经开发了一种无金属的光催化策略，用于在廉价的NH 4 SCN中以氮化碳（gC 3 N 4）作为绿色溶剂中的普通多相催化剂，在空气气氛下和蓝色LED的照射下制备硫氰化杂环。各种硫氰酸盐杂环，包括吲哚[2,1- a ]异喹啉-6（5 H）-one，苯并咪唑并[2,1- a ]异喹啉-6（5 H）-one，硫代黄酮，氮杂螺[4.5]三烯酮和咪唑[ 1,2-一以高产率（高达96％）成功合成了]吡啶。重要的是，这种无金属和无外部氧化剂的方法使用碳酸二甲酯作为绿色介质，避免了传统的挥发性有机溶剂。此外，可循环使用的gC 3 N 4催化剂可使用至少8次，而不会显着降低活性。
• [EN] PYRIMIDINE COMPOUNDS AND PYRIMIDO INDOLE COMPOUNDS AND METHODS OF USE<br/>[FR] COMPOSÉS DE PYRIMIDINE ET COMPOSÉS DE PYRIMIDO INDOLE ET PROCÉDÉS D'UTILISATION DE CEUX-CI
  申请人：UNIV HOLY GHOST DUQUESNE

  公开号：WO2016022890A1

  公开（公告）日：2016-02-11

  The present invention discloses substituted pyrimidine and pyrimido indole compounds and optionally pharmaceutically acceptable salts, hydrates or solvates thereof. A method of treating a patient having cancer or a disease comprising administering to a patient an effective amount of the compound or pharmaceutically acceptable salt, hydrate, or solvate thereof.

  本发明公开了取代嘧啶和嘧啶并吲哚化合物以及可选择的药用盐、水合物或溶剂化合物。一种治疗患有癌症或疾病的患者的方法包括向患者投予化合物或其药用盐、水合物或溶剂化合物的有效量。